Kiniksa Pharmaceuticals has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 50% of filings. The Australia(AU), European Patent Office(EPO), United States(US), and Poland(PL) patent Office are among the top ten patent offices where Kiniksa Pharmaceuticals is filings its patents. Among the top granted patent authorities, Kiniksa Pharmaceuticals has 50% of its grants in United States(US) and 50% in Poland(PL).
Regeneron Pharmaceuticals and Roche could be the strongest competitors for Kiniksa Pharmaceuticals
Patents related to rare diseases and addiction lead Kiniksa Pharmaceuticals’s portfolio
Kiniksa Pharmaceuticals has the highest number of patents in rare diseases followed by, addiction and Covid-19. For rare diseases, nearly 50% of patents were filed and 50% of patents were granted in Q2 2024.
Inflammation related patents lead Kiniksa Pharmaceuticals portfolio followed by pericarditis, and coronavirus disease 2019 (covid-19)
Kiniksa Pharmaceuticals has highest number of patents in inflammation followed by pericarditis, coronavirus disease 2019 (covid-19), cough, and pneumonia. For inflammation, nearly 5% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Kiniksa Pharmaceuticals‘s filings and grants, buy the databook here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.